Dec 13, 2021 / 10:30PM GMT
Operator
Greetings. Welcome to the Aptose Biosciences Corporate Update Call. (Operator Instructions). Please note, this conference is being recorded.
I will now turn the conference over to your host, Chairman and CEO, Dr. William Rice. You may begin.
William G. Rice - Aptose Biosciences Inc. - Chairman, President & CEO
Good afternoon, everyone, and welcome to our call for the Aptose corporate update event held in conjunction with the 2021 ASH Annual Meeting. As always, I'll remind you that today I will make certain forward-looking statements.
As many of you already know, Aptose is a clinical stage company, a biotech company that develops oral kinase inhibitors for the treatment of orphan hematologic malignancies. Our lead molecule is the recently in-licensed HM43239 or 239 as we will call it.
First and foremost, 239 is a clinically validated myeloid kinome inhibitor that potently inhibits a constellation of kinases, including the sixth FLT3 mutant forms of c-KIT and other kinases operative in myeloid malignancies such as AML. Already,
Aptose Biosciences Inc at Corporate Update Call Transcript
Dec 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers